Abstract: The disclosure relates to Cannabis plants having a distinct cannabinoid profile and limited psychoactive properties that can be suitable for medicinal uses associated with treating inflammation and chronic pain.

Abstract: The disclosure relates to Cannabis plants having a distinct cannabinoid profile and limited psychoactive properties that can be suitable for medicinal uses associated with treating inflammation and chronic pain.

Abstract: This present disclosure relates to a new and distinct Cannabis ruderalis+Humulus lupulus plant named ‘ANEW’ particularly characterized by flowers that autoflower ripen every 45-90 days and which are green or mottled with silver grey. Plant which may be propagated economically and uniformly using tissue culture, root grafting and produce a high yield 100% phytocannabinoid molecule “CBD” cannabidiol chemical name: (1?R,2?R)-5?-Methyl-4-pentyl-2?-(prop-1-en-2-yl)-1?,2?,3?,4?-tetrahydro-[1,1?-biphenyl]-2,6-diol with no or trace delta 9 “THC” tetrahydrocannabinol molecule that is used in many beneficial therapeutic uses. Allowing producers the opportunity to sell high yield and quality superplant producing only cannabidiol (CBD) autoflowers every 45-90 days.